JNJ-95597528

Phase 2Small molecule

Johnson & Johnson

JNJ-95597528 is one of 32 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaNot yet recruiting

Dermatitis, AtopicActive, not recruiting

AsthmaPhase 2

Not yet recruiting

Dermatitis, AtopicPhase 2

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

JNJ-95597528

Johnson & Johnson

Phase 2

1 3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Aclidinium Bromide

Atrovent

2 7

Ozone

TTanta University

Preclinical

1 8

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 9

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 10

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Dermatitis, Atopic

NCT07230860

Q3 2030

Phase 2Not yet recruiting

Asthma

NCT07746687

Clinical

Trials by Indication[1]

Asthma1 trial

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Inadequately Controlled Moderate to Severe Asthma

Not yet recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07746687·440 enrolled

Dermatitis, Atopic1 trial

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT07230860·189 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for JNJ-95597528. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-95597528 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-95597528. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Johnson & Johnson

JNJ-95597528

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2030

Trials by Indication[1]

Asthma1 trial

Dermatitis, Atopic1 trial

References

Drug Info

Quick Facts

Related News